Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

Acromegaly is due to hypersecretion of growth ... Medical treatment of the disease is usually with somatostatin analogs. An open, prospective, single-center study by Maiza et al.

with noncured acromegaly. Serum IGF-I and GH levels were measured by validated assays. In total, 81 patients had active disease (IGF-I and GH both high), 68 patients had biochemically controlled ...

Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is ...

A Prescription Drug User Fee Act target date of September 25, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...

In about 80% of families the gene causing the disease is unknown. The pituitary tumour types occurring in these families are most commonly growth hormone-secreting adenomas (causing acromegaly or ...

Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M ...